Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

FDA Invites Manufacturers, Ad Agencies To Discuss DTC Ad Designs

Executive Summary

FDA would like to consult with pharmaceutical companies and their advertising agencies early on in the development of direct-to-consumer advertising campaigns

You may also be interested in...



Ads For New Drugs Would Require FDA Preclearance Under Rx Safety Bill

Promotional materials for recently-approved drugs would receive special scrutiny by the Center for Postmarket Drug Evaluation & Research proposed in Senate legislation

Ads For New Drugs Would Require FDA Preclearance Under Rx Safety Bill

Promotional materials for recently-approved drugs would receive special scrutiny by the Center for Postmarket Drug Evaluation & Research proposed in Senate legislation

Celebrex, Bextra Ads Draw Fire From FDA; Reminder Of “Reminder” Ad Rules

An FDA "untitled" letter to Pfizer on Celebrex and Bextra is the agency's second recent objection to the company's interpretation of the boundaries of "reminder" ads

Related Content

UsernamePublicRestriction

Register

ID036688

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel